Country

Clinical trials in Germany

Active obesity and GLP-1 studies with at least one location in Germany.

95active studies

49recruiting now

40countries represented

229largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 3

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Obesity, Weight GainCondition

Tirzepatide, PlaceboTreatment

Argentina, Australia69 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06439277See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Obesity, OverweightCondition

Ribupatide, PlaceboTreatment

Argentina, Australia104 locations

KaileraSponsor

Updated 2026-09-03 · NCT07284875See eligibility →

Recruiting nowPhase 3

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

ObesityCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Argentina, Australia72 locations

Novo Nordisk A/SSponsor

Updated 2026-08-27 · NCT07503210See eligibility →

Recruiting nowPhase 2

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Type 2 DiabetesCondition

LY3457263, PlaceboTreatment

Canada, Germany60 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT06897475See eligibility →

Recruiting nowNot applicable

Shift Workers' Health Behavior Action Program Across Europe

Night Shift Work, Obesity & OverweightCondition

Combined Lifestyle InterventionTreatment

Germany, Netherlands5 locations

Wageningen UniversitySponsor

Updated 2026-08-20 · NCT07631767See eligibility →

Recruiting nowPhase 3

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

ASC30 tablets A1, PlaceboTreatment

Czechia, Germany136 locations

Ascletis Pharma (China) Co., LimitedSponsor

Updated 2026-08-14 · NCT07743450See eligibility →

Recruiting nowPhase 3

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ASC30 tablets A1, PlaceboTreatment

Canada, Czechia120 locations

Ascletis Pharma (China) Co., LimitedSponsor

Updated 2026-08-14 · NCT07743463See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil57 locations

AmgenSponsor

Updated 2026-08-14 · NCT07226765See eligibility →

Recruiting nowEarly Phase 1

A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity

Healthy Participants Study, Overweight and Obese AdultsCondition

ZP6590, solution for injection, Placebo, solution for injectionTreatment

Germany1 locations

Zealand PharmaSponsor

Updated 2026-08-13 · NCT07721597See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

UBT251, UBT251 PlaceboTreatment

Australia, Germany70 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07668388See eligibility →

Recruiting nowPhase 3

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China92 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07571109See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Obesity, Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil61 locations

AmgenSponsor

Updated 2026-08-04 · NCT07225686See eligibility →

Recruiting nowPhase 1, Phase 2

A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D

Obesity, Type 2 DiabetesCondition

GUB-UCN2, PlaceboTreatment

Germany1 locations

Gubra A/SSponsor

Updated 2026-07-29 · NCT07702890See eligibility →

Recruiting nowPhase 1

A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Germany, Sweden2 locations

Eli Lilly and CompanySponsor

Updated 2026-07-16 · NCT07665879See eligibility →

Recruiting nowPhase 3

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China80 locations

Novo Nordisk A/SSponsor

Updated 2026-07-13 · NCT07571005See eligibility →

Recruiting nowPhase 3

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

ObesityCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Argentina, Australia72 locations

Novo Nordisk A/SSponsor

Updated 2026-07-09 · NCT07339423See eligibility →

Recruiting nowPhase 4

Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity

Bardet Biedl Syndrome (BBS), Bardet Biedl SyndromeCondition

SetmelanotideTreatment

Germany1 locations

Tom HühneSponsor

Updated 2026-06-29 · NCT07674290See eligibility →

Recruiting nowPhase 1

A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity

Obesity, OverweightCondition

Cagrilintide D, Cagrilintide B and placebo semaglutide ITreatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2026-06-26 · NCT07597018See eligibility →

Recruiting nowPhase 1

A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity

Type 1 Diabetes (T1D), OverweightCondition

NNC0497-0040, PlaceboTreatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2026-06-04 · NCT07578584See eligibility →

Recruiting nowPhase 1

A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity

Overweight, ObesityCondition

Cagrilintide, Placebo CagrilintideTreatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2026-05-15 · NCT07557953See eligibility →

Recruiting nowNot applicable

Validation of Energy Expenditure Measures Study

Obesity Prevention, HealthyCondition

Intervention not listedTreatment

Germany1 locations

University of LeipzigSponsor

Updated 2026-04-30 · NCT07155564See eligibility →

Recruiting nowPhase 1

A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity

ObesityCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Germany1 locations

Novo Nordisk A/SSponsor

Updated 2026-04-27 · NCT07508020See eligibility →

Recruiting nowNot applicable

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

Colorectal Cancer, Early Onset Colorectal CancerCondition

Semi Quantitative Food Frequency Questionnaire (SQFFQ)Treatment

Finland, Germany8 locations

San Raffaele UniversitySponsor

Updated 2026-04-24 · NCT05732623See eligibility →

Recruiting nowNot applicable

The ISAR InflEx Trial (Inflammation and Exercise)

Inflammation, Obesity (Disorder)Condition

moderate-intensity exercise, vigorous-intensity exerciseTreatment

Germany1 locations

Department of Cardiology German Heart Center Munich TUM University HospitalSponsor

Updated 2026-04-24 · NCT07543666See eligibility →

Recruiting nowNot applicable

Effects of a 6-months Fiber- and Polyphenol-rich Diet on Brain Inflammatory Processes in Perimenopausal Women Living With Overweight or Obesity

Overweight and/or Obesity, Perimenopausal WomenCondition

Polybiotic dietary intervention, PlaceboTreatment

Germany1 locations

Max Planck Institute for Human Cognitive and Brain SciencesSponsor

Updated 2026-03-30 · NCT07501377See eligibility →

Recruiting nowPhase 3

A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults

Monogenic ObesityCondition

MibavademabTreatment

Germany1 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-03-10 · NCT07220772See eligibility →

Recruiting nowNot applicable

Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice

Monogenic ObesityCondition

Semaglutide (administered by PDS290 pen-injector)Treatment

France, Germany7 locations

Prof. Dr. Martin WabitschSponsor

Updated 2026-01-08 · NCT07302802See eligibility →

Recruiting nowPhase 4

A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese

Polycystic Ovary Syndrome (PCOS), Obesity & OverweightCondition

Tirzepatide as an adjunct to lifestyle intervention, Placebo as an adjunct to lifestyle interventionTreatment

Germany2 locations

University of BonnSponsor

Updated 2026-01-08 · NCT07326111See eligibility →

Recruiting nowNot applicable

International Genetic Obesity Registry

Genetic ObesityCondition

Intervention not listedTreatment

Germany1 locations

University of UlmSponsor

Updated 2025-12-22 · NCT07296900See eligibility →

Recruiting nowPhase 4

A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease

Chronic Kidney Disease(CKD)Condition

Dapagliflozin, SemaglutideTreatment

Denmark, Germany4 locations

Peter RossingSponsor

Updated 2025-11-20 · NCT07239570See eligibility →

Recruiting nowNot applicable

Precise Eating Time to Improve Glycemic Control and Cardiometabolic Health in Prediabetes and Diabetes

Prediabetes, Type 2 DiabetesCondition

Early Time-Restricted Eating, Late Time-Restricted EatingTreatment

Germany1 locations

German Institute of Human NutritionSponsor

Updated 2025-09-12 · NCT07171281See eligibility →

Recruiting nowNot applicable

The Effect of Mediterranean Diet and Mindfulness Eating on Depression Severity in People With Obesity and Major Depressive Disorder

Depressive Disorder, MajorCondition

nutritional intervention, Mindful EatingTreatment

Germany1 locations

University Hospital TuebingenSponsor

Updated 2025-04-08 · NCT06621394See eligibility →

Recruiting nowNot applicable

Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness

Normal Weight, Overweight and ObesityCondition

Subcutaneous GLP1-RA, Subcutaneous placeboTreatment

Germany1 locations

University Hospital TuebingenSponsor

Updated 2025-03-30 · NCT06487832See eligibility →

Recruiting nowNot applicable

Effects of Intermittent Fasting and Exercise on Inflammation, Metabolism, and the Microbiome in Metabolic Syndrome

Metabolic Syndrome, Obesity and Obesity-related Medical ConditionsCondition

Alternate day fasting, Time restricted eatingTreatment

Germany1 locations

University of Erlangen-Nürnberg Medical SchoolSponsor

Updated 2025-03-20 · NCT06885255See eligibility →

Recruiting nowNot applicable

Cohort Study on Plant-based Diets (COPLANT Study)

Dietary Exposure, Diabetes Mellitus, Type 2Condition

Intervention not listedTreatment

Austria, Germany8 locations

German Federal Institute for Risk AssessmentSponsor

Updated 2025-02-14 · NCT06323538See eligibility →

Recruiting nowNot applicable

The Effect of Bariatric Surgery on Insulin Sensitivity and Energy Metabolism

Obesity, Diabetes Mellitus, Type 2Condition

surgeryTreatment

Germany1 locations

German Diabetes CenterSponsor

Updated 2025-01-10 · NCT01477957See eligibility →

Recruiting nowNot applicable

AI-POD Clinical Validation Study for Obese Patients

Acute Cardiovascular DiseaseCondition

Non InterventionalTreatment

Austria, Belgium6 locations

University Hospital, BonnSponsor

Updated 2024-09-19 · NCT06595134See eligibility →

Recruiting nowNot applicable

Global Research Initiative for Patients Screening on MASH

MASH, MASLDCondition

Intervention not listedTreatment

Belgium, Czechia13 locations

Julius ClinicalSponsor

Updated 2024-08-01 · NCT05651724See eligibility →

Recruiting nowNot applicable

Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases

NAFLD, Diabetes MellitusCondition

Oral glucose tolerance test, Liver UltrasoundTreatment

Germany1 locations

Technische Universität DresdenSponsor

Updated 2024-05-02 · NCT06396871See eligibility →

Recruiting nowNot applicable

Exercise Training on Brain Insulin Responsiveness

Insulin Resistance, ObesityCondition

single bout of moderate intensity continuous training (MICT), single bout of High Intensity Interval Training (HIIT)Treatment

Germany1 locations

University Hospital TuebingenSponsor

Updated 2023-11-08 · NCT06039787See eligibility →

Recruiting nowNot applicable

Leipzig Adipose Tissue Childhood Cohort

Childhood Obesity, Insulin ResistanceCondition

Intervention not listedTreatment

Germany1 locations

University of LeipzigSponsor

Updated 2023-11-07 · NCT02208141See eligibility →

Recruiting nowNot applicable

CrescNet - Growth Monitoring Network

Obesity, Child DevelopmentCondition

Intervention not listedTreatment

Germany1 locations

University of LeipzigSponsor

Updated 2023-11-07 · NCT03072537See eligibility →

Recruiting nowNot applicable

Leipzig Childhood Obesity Study

Childhood ObesityCondition

Intervention not listedTreatment

Germany1 locations

University of LeipzigSponsor

Updated 2023-11-07 · NCT04491344See eligibility →

Recruiting nowNot applicable

The European NAFLD Registry

NAFLD, NASHCondition

Intervention not listedTreatment

Belgium, Finland37 locations

Newcastle UniversitySponsor

Updated 2023-01-06 · NCT04442334See eligibility →

Recruiting nowNot applicable

Impact of Microbiome-changing Interventions on Food Decision-making

Overweight and ObesityCondition

Inulin, Lifestyle interventionTreatment

Germany1 locations

Max Planck Institute for Human Cognitive and Brain SciencesSponsor

Updated 2022-04-29 · NCT05353504See eligibility →

Recruiting nowNot applicable

Hamburg City Health Study - a German Cohort Study

Coronary Heart Disease, StrokeCondition

Intervention not listedTreatment

Germany1 locations

Universitätsklinikum Hamburg-EppendorfSponsor

Updated 2019-05-02 · NCT03934957See eligibility →

Recruiting nowNot applicable

Pilot Project on Interdisciplinary Therapy of Obesity

Obesity, Weight LossCondition

Laparoscopic gastric sleeve, Gastric BandingTreatment

Germany3 locations

University of HohenheimSponsor

Updated 2018-10-26 · NCT01344525See eligibility →

Opening soonPhase 1

A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or Obesity

Overweight, ObesityCondition

BI 3034701, PlaceboTreatment

Germany1 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07754474See eligibility →

Opening soonPhase 3

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Overweight, Prediabetic StateCondition

Orforglipron, PlaceboTreatment

Argentina, China179 locations

Eli Lilly and CompanySponsor

Updated 2026-08-31 · NCT07794579See eligibility →

Opening soonPhase 4

Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide

Obesity (BMI>30)Condition

Dual GIP/GLP-1 Receptor Agonist Tirzepatide, Resistance TrainingTreatment

Germany1 locations

Technical University of MunichSponsor

Updated 2026-08-20 · NCT07777575See eligibility →

Opening soonPhase 1

A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity

Healthy, ObesityCondition

Survodutide formulation A, Survodutide formulation B2Treatment

Germany1 locations

Boehringer IngelheimSponsor

Updated 2026-08-18 · NCT07768813See eligibility →

Opening soonNot applicable

Combining Fasting and Fibre Interventions to Optimise Their Gut Microbiome-mediated Health Benefits

Fasting, Dietary FibreCondition

Fibre Arm, Control ArmTreatment

Germany1 locations

Buchinger Wilhelmi Development & Holding GmbHSponsor

Updated 2026-07-09 · NCT07691736See eligibility →

Opening soonNot applicable

Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)

Severe Mental Illness, Depression / Major Depressive DisorderCondition

Semaglutide (SEMA), Exercise moduleTreatment

Austria, Germany5 locations

Ludwig-Maximilians - University of MunichSponsor

Updated 2026-05-14 · NCT07586150See eligibility →

Opening soonNot applicable

The Importance of Insulin Action in the Brain for the Immune System During Physical Activity-Overweight

Insulin SensitivityCondition

Spiroergometer test with intranasal insulin spray, Spiroergometer test with intranasal placebo sprayTreatment

Germany1 locations

University of UlmSponsor

Updated 2026-03-16 · NCT07466173See eligibility →

Opening soonPhase 3

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Obesity, OverweightCondition

NNC0487-0111, SemaglutideTreatment

Argentina, Brazil120 locations

Novo Nordisk A/SSponsor

Updated 2026-03-12 · NCT07400107See eligibility →

Opening soonNot applicable

Multicentric Approval Study Trans-Duodenal Barrier for Typ 2 Diabetes With Obesity

Typ 2 Diabetes, ObesityCondition

endoscopic implantTreatment

Germany8 locations

Trans-Duodenal Concepts GmbHSponsor

Updated 2026-02-18 · NCT07417683See eligibility →

Opening soonNot applicable

Exercise, Chronotype, and Prediabetes

Prediabetes, Overweight , ObesityCondition

Timing of exercise, Timing of exerciseTreatment

Germany1 locations

German Diabetes CenterSponsor

Updated 2026-02-05 · NCT07389005See eligibility →

Opening soonNot applicable

Empowering Healthy Lifestyle Personalised Intervention to Prevent and Control Obesity: The HealthyW8 Project

Obesity Prevention, Obesity and OverweightCondition

Intervention GroupTreatment

Bulgaria, Denmark13 locations

Fundació d'investigació Sanitària de les Illes BalearsSponsor

Updated 2025-07-01 · NCT07011368See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

Related countries

United States1,107 China326 Canada158 France110 Spain98

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.